Cognition Therapeutics Cost Of Revenue Over Time
| CGTX Stock | USD 0.43 0 0.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cognition Therapeutics Performance and Cognition Therapeutics Correlation. Cognition |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cognition Therapeutics. If investors know Cognition will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cognition Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Return On Assets (0.94) | Return On Equity (1.08) |
The market value of Cognition Therapeutics is measured differently than its book value, which is the value of Cognition that is recorded on the company's balance sheet. Investors also form their own opinion of Cognition Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cognition Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cognition Therapeutics' market value can be influenced by many factors that don't directly affect Cognition Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cognition Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cognition Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cognition Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Cognition Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 23 K | 45 K | 72 K | 118 K | 126 K | 132.3 K |
| DMAC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5 K | 2.2 K | 4 K | 0.0 | 21 K | 21 K | 24 K | 25 K | 30 K | 31.5 K |
| VALN | 475 K | 6.7 M | 11.1 M | 16.5 M | 17.1 M | 47 M | 43.1 M | 46 M | 43.4 M | 50 M | 54.3 M | 187.9 M | 324.4 M | 100.9 M | 58.6 M |
| VANI | 4.4 M | 4.4 M | 4.4 M | 5.6 M | 3.6 M | 5.3 M | 10.1 M | 5.1 M | 4.9 M | 2.2 M | 167 K | 345 K | 381 K | 357 K | 339.1 K |
| DNLI | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75.7 M | 74.5 M | 143.2 M | 193.4 M | 212.6 M | 5.6 M | 7 M | 16.7 M | 15.9 M |
| DNTH | 6 K | 6 K | 6 K | 6 K | 6 K | 6 K | 6 K | 376 K | 875 K | 1.8 M | 2 M | 2 M | 147 K | 355 K | 337.2 K |
| DOMH | 5.2 M | 388.1 K | 3 K | 3 K | (188 K) | (188 K) | (188 K) | (188 K) | (188 K) | (188 K) | (188 K) | (188 K) | (188 K) | 442 K | 419.9 K |
| VCEL | 9.6 M | 4 K | 6 K | 4 K | 17.3 M | 26.5 M | 28.3 M | 30.4 M | 32.2 M | 37.6 M | 40 M | 50.2 M | 54.6 M | 61.9 M | 65 M |
| VCNX | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 115 K | 160 K | 1 M | 199 K | 2 K | 169 K | 207 K | 16.6 M | 17.4 M |
| VCYT | 2.9 M | 2.9 M | 7.6 M | 12.6 M | 16.6 M | 21.5 M | 25.5 M | 28.2 M | 33.1 M | 36.5 M | 41.5 M | 74.4 M | 101.6 M | 112.9 M | 118.5 M |
Cognition Therapeutics and related stocks such as Equillium, DiaMedica Therapeutics, and Valneva SE ADR Cost Of Revenue description
Cost of Revenue is found on Cognition Therapeutics income statement and represents the costs associated with goods and services Cognition Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
| Cognition Therapeutics | CGTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.434
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.